Oramed Pharmaceuticals (NASDAQ:ORMP) Posts Earnings Results, Misses Expectations By $0.01 EPS

Key Points

• Oramed Pharmaceuticals reported a quarterly earnings loss of ($0.05) EPS, missing analysts' expectations by $0.01.
• The company's stock traded down 1.9% to $2.08, with a market capitalization of $84.96 million.
• Jane Street Group LLC increased its stake in Oramed by 35.3%, now owning approximately 0.16% of the company.

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.01), Zacks reports.

Oramed Pharmaceuticals Trading Down 1.9%

Oramed Pharmaceuticals stock traded down $0.04 during trading on Friday, hitting $2.08. The company had a trading volume of 132,549 shares, compared to its average volume of 71,817. Oramed Pharmaceuticals has a 1-year low of $1.82 and a 1-year high of $3.09. The company's 50 day simple moving average is $2.15 and its 200-day simple moving average is $2.21. The stock has a market cap of $84.96 million, a price-to-earnings ratio of -5.94 and a beta of 1.60.

Hedge Funds Weigh In On Oramed Pharmaceuticals

An institutional investor recently raised its position in Oramed Pharmaceuticals stock. Jane Street Group LLC grew its holdings in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) by 35.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 67,173 shares of the biotechnology company's stock after acquiring an additional 17,510 shares during the period. Jane Street Group LLC owned about 0.16% of Oramed Pharmaceuticals worth $144,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 12.73% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen downgraded shares of Oramed Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, May 17th.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.